Royalty Report: Supply, Medical, Tissue – Collection: 183951

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Supply
  • Medical
  • Tissue
  • Regenerative medicine
  • Drugs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 183951

License Grant
The Israeli Licensor, a R&D business segment of a University, grants to the Licensee and/or its affiliates an exclusive, worldwide license, under Licensors rights in the Licensor Technology for the sole purpose of developing, manufacturing, using, offering for sale and selling the Products. The Company and its Affiliates shall be entitled to grant Sublicenses to third parties.
License Property
The technology is relating to coral based and non-coral based conditioned medium for tissue regeneration and repair.

62/443,826 Methods, compositions and devices related to neural cell development

Field of Use
This agreement is for the medical industry.

IPSCIO Record ID: 288845

License Grant
The Licensor, a wholly owned subsidiary of an Israeli University and the Licensee agree that this Agreement shall supersede the License Agreement which is hereby terminated and shall have no further force and effect.   The original agreement was an exclusive worldwide license in Licensors patents and know-how to develop and commercialize products based on or incorporating coral-based conditioned medium for neuronal tissue regeneration and/or repair.
License Property
The services agreements related to laboratory access and other services.
Field of Use
The Field of Use shall mean treatments of traumatic brain injuries.

The Licensee received an exclusive worldwide royalty-bearing license in Licensor's patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Licensor's research or technology or the Licensee's research funding.

IPSCIO Record ID: 257469

License Grant
The Israeli Licensor, the technology transfer company of the University, grants the Licensee of Israel an exclusive worldwide license in respect of Licensors rights in and to the Licensed Information and the Joint Patents, for the development, by the Licensee or by a Subcontractor on the Licensees behalf, manufacture, production, use, marketing, distribution, offering for sale, export and import and sale of the Licensed Products.

For the removal of doubt, nothing contained in this Agreement shall prevent Licensor or the Institute from using the Licensed Information for academic research or other scholarly purposes.

License Property
The property is the plasmid p80 BS and methods of use thereof.

The patent is titled High Level Expression of Heterologous Proteins.

Heterologous proteins – in cell biology and protein biochemistry, heterologous expression means that a protein is experimentally put into a cell that does not normally make (i.e., express) that protein.

Field of Use
Licensee is a biotechnology company focused on modulating the fibroblast growth factor system to enable it to create more effective solutions for tissue regeneration.  This agreement discusses application for paediatric use.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.